



Rubicon Biotechnology and MosaMedix Announce License Agreement Rubicon to License MosaMedix's Annexin A5 Technology as a Phosphatidylserine Targeting Agent for Treatment of Solid Tumors

Lake Forest, CA – July 7th, 2015

Rubicon Biotechnology, LLC (www.rubiconbio.com) is pleased to announce that it has entered into an agreement with MosaMedix B.V. to acquire the exclusive worldwide license for an engineered variant of Annexin A5, a natural protein that directly binds to phosphatidylserine (PS) with high affinity. With this license, Rubicon will have world-wide rights for MosaMedix's breakthrough Annexin A5 variant that has been modified to prohibit the molecule's cellular internalization. Rubicon intends to study the Annexin A5 variant for the treatment of solid tumors.

MosaMedix B.V. (www.mosamedix.com) licenses the work of Dr. Chris Reutelingsperger and his group at Maastricht University. Professor Reutelingsperger discovered Annexin A5 in 1983 and has spent his career studying PS binding proteins, particularly the adaptation of annexins for clinical and diagnostic uses. In 1994, he invented an apoptosis detection assay using Annexin A5 that has become a standard assay in laboratories world-wide. In 1999, he initiated the first clinical study in which Annexin A5 was used as an imaging agent to visualize and localize apoptosis in patients, hence providing physicians with a valuable tool in the therapeutic decision-making process. For the research market, he developed Annexin A5 as an in vivo fluorescent imaging agent, now marketed internationally by Perkin Elmer. He has successfully translated his discoveries with Annexin A5 into important tools for the life science industry.

As the pre-eminent researcher of PS-binding proteins, his work has led to the design, construction and manufacture of new Annexin-A5 derivatives. Dr. Missag H. Parseghian, Chief Scientific Officer at Rubicon, comments "We are very fortunate to be working with Dr. Chris Reutelingsperger, who first discovered Annexin A5 and the inventor who engineered this important variant. Dr. Reutelingsperger will provide invaluable assistance given his knowledge of the interaction between Annexin A5 and phosphatidylserine."

"We are very pleased to work with Rubicon. We look forward to a development that releases the full potential of combined know-how and technology for the creation of effective, targeted cancer treatments", said Peter Moonen, CEO at MosaMedix.

About Rubicon Biotechnology

[Rubicon Biotechnology](#) is a privately held biotechnology company that develops targeted, life-saving technologies in the areas of defense countermeasures, cardiology, neurology and oncology. Rubicon has in-licensed two platform technologies for drug development. The first is "Antibody Mediated Transduction of Heat Shock Proteins into Living Cells" from the Veterans Administration. This technology delivers heat shock protein, a key protein which saves injured cells that suffer hypoxic and oxidative stresses that occur following unfortunately common tissue injuries, such as heart attack, stroke and traumatic brain injury. The second technology, "Modified Non-Internalizing A5 Variants," licensed from MosaMedix N.V., delivers immunostimulants to tumors in order to enhance the immune system's ability to fight cancer. With support from several SBIR and CounterACT grants, and in collaboration with major institutions in the U.S., Rubicon is developing these targeted therapies with the goal of improving health outcomes and saving lives.

About MosaMedix

Mosamedix's technology comprises a deep knowledge and expertise about Annexin A5, a 36 kD protein, and its structure/function relationship to bind selectively to cells executing cell death. MosaMedix Annexin Technology Platform (ATP) powers the generation of a wide range of diagnostic & therapeutic compounds combining the targeting function of annexin A5 with drugs or drug carriers or diagnostic agents. MosaMedix B.V. holds patents and has filed patent applications for several engineered variants together with claims for potential diagnostic and therapeutic uses in a wide range of serious medical conditions, such as cancers, cardiovascular and autoimmune diseases.



MosaMedix owns patents on engineered Annexins that have unique properties which are highly desirable for imaging and drug targeting applications.

The derivatives are engineered to target diseased tissues with visual reporters or therapeutic payloads. The objective of MosaMedix is to realize translation of this technology into applications for monitoring and treating diseases, such as selected cancers, chronic inflammation and cardiovascular disease.

For the Research Market the company has developed an in vivo Fluorescence Imaging application, which is now marketed worldwide by Perkin Elmer.

###